PLOD1 and bile duct carcinoma: To compare in vivo antitumor effects of the hEx3-LH and hEx3-LH mutants, we transplanted mixtures of human bile duct carcinoma (TFK-1) cells and lymphokine-activated killer cells with the T-cell phenotype (T-LAK) cells into severe combined immunodeficient (SCID) mice, which were then treated for four days with bsDbs.